T
Turbine AI
Biotech & Life Sciences · Budapest, Hungary · Founded 2016
Simulation-driven drug discovery company delivering population targeted cancer therapies MoreLess
Turbine AI has developed a cell simulation platform that uses machine learning to model human biology and predict the effectiveness of cancer treatments. This technology, called Simulated Cells™, aims to improve the drug discovery and development process by identifying promising therapeutic targets and patient populations that are most likely to respond to treatment.
The company collaborates with pharmaceutical companies, such as AstraZeneca, to apply its simulation platform to specific challenges in oncology, like understanding drug resistance in hematological cancers. By simulating how cancer cells behave at a molecular level, Turbine AI can provide insights that are difficult to obtain through traditional laboratory experiments alone.
The platform is designed to de-risk drug development, potentially reducing the time and cost associated with bringing new therapies to market. The company offers a "Virtual Lab" for potential clients to explore the technology's capabilities.
Keywords: cell simulation, oncology, drug discovery, machine learning, personalized medicine, cancer treatment, R&D, biotechnology, pharmaceutical, hematology
Talent graph
Turbine AI's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Turbine AI has talent and traffic
team presence
Market sentiment
What the market is saying about Turbine AI
An AI-synthesized read of the highest-engagement posts about Turbine AI on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Turbine AI on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.














